RT Journal Article
SR Electronic
T1 Wastewater Monitoring of SARS-CoV-2 from Acute Care Hospitals Identifies Nosocomial Transmission and Outbreaks
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.20.21251520
DO 10.1101/2021.02.20.21251520
A1 Acosta, Nicole
A1 A. Bautista, María
A1 Hollman, Jordan
A1 McCalder, Janine
A1 Beaudet, Alexander Buchner
A1 Man, Lawrence
A1 Waddell, Barbara J.
A1 Chen, Jianwei
A1 Li, Carmen
A1 Kuzma, Darina
A1 Bhatnagar, Srijak
A1 Leal, Jenine
A1 Meddings, Jon
A1 Hu, Jia
A1 Cabaj, Jason L.
A1 Ruecker, Norma J.
A1 Naugler, Christopher
A1 Pillai, Dylan R.
A1 Achari, Gopal
A1 Ryan, M. Cathryn
A1 Conly, John M.
A1 Frankowski, Kevin
A1 Hubert, Casey RJ
A1 Parkins, Michael D.
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.20.21251520.abstract
AB Background SARS-CoV-2 has been detected in wastewater and its abundance correlated with community COVID-19 cases, hospitalizations and deaths. We sought to use wastewater-based detection of SARS-CoV-2 to assess the epidemiology of SARS-CoV-2 in hospitals.Methods Between August and December 2020, twice-weekly wastewater samples from three tertiary-care hospitals (totaling >2100 dedicated inpatient beds) were collected. Wastewater samples were concentrated and cleaned using the 4S-silica column method and assessed for SARS-CoV-2 gene-targets (N1, N2 and E) and controls using RT-qPCR. Wastewater SARS-CoV-2 as measured by quantification cycle (Cq), genome copies and genomes normalized to the fecal biomarker PMMoV were compared to the total daily number of patients hospitalized with active COVID-19, confirmed cases of hospital-acquired infection, and the occurrence of unit-specific outbreaks.Results Of 165 wastewater samples collected, 159 (96%) were assayable. The N1-gene from SARS-CoV-2 was detected in 64.1% of samples, N2 in 49.7% and E in 10%. N1 and N2 in wastewater increased over time both in terms of amount of detectable virus and the proportion of samples that were positive, consistent with increasing hospitalizations (Pearson’s r=0.679, P<0.0001, Pearson’s r=0.728, P<0.0001, respectively). Despite increasing hospitalizations through the study period, wastewater analysis was able to identify incident nosocomial-acquired cases of COVID-19 (Pearson’s r =0.389, P<0.001) and unit-specific outbreaks by increases in detectable SARS-CoV-2 N1-RNA (median 112 copies/ml) versus outbreak-free periods (0 copies/ml; P<0.0001).Conclusions Wastewater-based monitoring of SARS-CoV-2 represents a promising tool for SARS-CoV-2 passive surveillance and case identification, containment, and mitigation in acute-care medical facilities.Key-points summary SAS-CoV-2 RNA is detectable in hospital wastewater. Wastewater SARS-CoV-2 RNA increases in conjunction with COVID-19-related hospitalizations. Spikes in SARS-CoV-2 wastewater signal correspond to incident hospital-acquired cases and outbreaks, suggesting passive surveillance via wastewater has great promise for COVID-19 monitoring.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Canadian Institute of Health Research [448242 to M.D.P.]; and Canadian Foundation for Innovation [41054 to C.R.J.H], as well as discretionary start-up funding from the Cumming School of Medicine Infectious Disease Section-Chief Fund (M.D.P.) and Campus Alberta Innovates Program Chair (C.R.J.H).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by University of Calgary, Conjoint Health Region Ethics BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available after appropriate peer review when the manuscript is published.